Xtant Medical Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held on July 23, 2024. The Company, incorporated in Delaware, is a medical device manufacturer. As of the record date (May 28, 2024), there were 130,268,590 shares of Common Stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A quorum was established with 105,850,527 shares present (81.25% of outstanding shares). Stockholders voted on three proposals:
- Proposal One (Election of Directors): All six nominees were elected. Significant broker non-votes (13,377,172) were recorded for each director.
- Proposal Two (Ratification of Auditors): Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- Proposal Three (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of the named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific vote counts for each director nominee, noting the high volume of broker non-votes.
- Confirm the ratification of Grant Thornton LLP as the auditor for the 2024 fiscal year.
- Review the definitive proxy statement filed on June 10, 2024, for details on the executive compensation approved in Proposal Three.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.